Regeneron slides after its joint phase 3 trial of Kevzara in COVID-19 patients did not meet primary, secondary endpoints Check out this evening's top movers from around Wall Street, compiled by The Fly.
HIGHER
- GlaxoSmithKline (GSK) up 0.7% after its ViiV Healthcare announces FDA approval of Rukobia for HIV
LOWER
- United Insurance (UIHC) down 1.9% after estimate of Q2 catastrophe losses
- Regeneron (REGN) down 1.9% after ph.3 data on Kevzara in Covid patients
did not meet primary, secondary endpoints
Symbols:
GSK UIHC REGN - $620.76 /
+11.54 (+1.89%)
Keywords: fly intel, wall street, afterhours, movers, top stories, stocks